Oracle, AstraZeneca to Explore AI for Trial Recruiting

Oracle and AstraZeneca have agreed to explore how AI and real-world health data could help doctors find patients for clinical trials. Oracle announced the collaboration on 20 October 2026, from Austin, Texas and Abu Dhabi. The work will combine AstraZeneca’s scientific and therapeutic expertise with Oracle’s health data, cloud, AI, analytics and clinical workflow tools.

This is an early-stage arrangement. Oracle says it is a non-binding agreement under which the companies “plan to explore selected use cases”. No money, timetable or participating health systems were disclosed. The target is a long-standing bottleneck: recruiting enough eligible patients, which Oracle calls “one of the largest obstacles in clinical trials”.

In brief

Oracle and AstraZeneca signed a non-binding agreement to explore using AI and real-world data to help care teams identify eligible trial patients earlier.
Disease areas to be explored could include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunology; and rare diseases.
No financial terms, dates or named health systems were announced; the companies plan to set shared governance and outcome measures first.

What the companies plan to explore

According to Oracle, the companies “plan to explore selected use cases that could improve clinical-trial efficiency and success by leveraging modern applications and AI to help care teams identify eligible patients earlier and easier”. The aim is greater access to trials for patients in need.

Beyond recruitment, Oracle says the collaboration could help accelerate evidence generation and bring relevant research insights into everyday care. The companies intend to explore a “continuous learning model”, in which insights from research and routine care help inform future study design, safety monitoring and patient care.

Oracle lists the initial disease areas that “could” be explored: oncology; cardiovascular, renal and metabolic diseases; respiratory and immunology; and rare diseases. These are areas where AstraZeneca already has large research programmes. The announcement covers trials and care, not discovering new drugs.

What the executives said

“This unique collaboration brings leaders in healthcare and AI together at a global scale to accelerate the journey from the discovery of medicine to patient care,” said Pascal Soriot, AstraZeneca’s chief executive. He said combining the two companies could “help clinicians identify patients sooner, optimize clinical trials, and generate evidence continuously across the lifecycle of a medicine.”

“Some of the most important opportunities for AI are in healthcare, where better use of data can help turn scientific innovation into better outcomes for patients,” said Mike Sicilia, Oracle’s chief executive.

Anne-Claire Gerbaldi, AstraZeneca’s chief digital, data and AI officer, said: “Too many patients are diagnosed late or face a long journey to get the care they need.” Seema Verma, who leads Oracle Health and Life Sciences, said the work could help health systems find eligible patients sooner, “all under the governance of the health systems delivering care.”

Governance before scale

The companies have not said when any pilots will start. Oracle says they “plan to establish shared governance, reusable technical components, and agreed outcome measures to assess results”. Only then would they decide whether successful approaches could extend across disease areas and geographies.

That emphasis on governance matters. Using real-world patient records to match people to trials raises questions about consent, privacy and who controls the data. Verma’s comment suggests the health systems providing care, not the two companies, would remain in charge of their patients’ data, though the announcement gives no detail on how that would work.

Our read

Patient recruitment is one of the slowest and most expensive parts of drug development, so a pharma giant teaming up with the owner of a large electronic health record business is a logical pairing. But this is a statement of intent, not a contract with targets. The things to watch are whether named health systems sign up, which disease area goes first, and whether the outcome measures the companies promise are ever published.